Policy Brief 1: The Incremental Cost of Introducing Xpert MTB/RIF into the South African National TB Programme

By  Dr Gesine Meyer-Rath  Dr. Lawrence Long  Dr. William Macleod  Professor Ian Sanne  Kate Bistline  Wendy Stevens  Professor Sydney Rosen  |  | 

Background

South Africa bears a large share of the global burden of HIV/tuberculosis co-infection. The Cepheid GeneXpert System using the Xpert MTB/RIF assay http://www.cepheid.com/systems-and-software/genexpert-system/), a cassette-based cartridge, has provided the possibility of a rapid, point-of-care diagnosis of tuberculosis (TB) and, simultaneously, a rapid screen for rifampicin (RIF) resistance. The assay is highly sensitive and specific for M. tuberculosis (MTB) infection and received a strong recommendation from the World Health Organization (WHO) in December 2010 as the initial test in individuals suspected of multi-drug resistant (MDR) tuberculosis and those with HIV co-infection. Policy Brief 1–Xpert TB diagnosis cost in South Africa, July 2011

 

 

Publication details

PDF